- Home
- PHT vs YMAB Comparison
PHT vs YMAB Comparison
Compare PHT & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- YMAB
- Stock Information
- Founded
- PHT 2002
- YMAB 2015
- Country
- PHT United States
- YMAB United States
- Employees
- PHT N/A
- YMAB N/A
- Industry
- PHT Investment Managers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- YMAB Health Care
- Exchange
- PHT Nasdaq
- YMAB Nasdaq
- Market Cap
- PHT 237.1M
- YMAB 192.4M
- IPO Year
- PHT N/A
- YMAB 2018
- Fundamental
- Price
- PHT $8.06
- YMAB $4.30
- Analyst Decision
- PHT
- YMAB Buy
- Analyst Count
- PHT 0
- YMAB 10
- Target Price
- PHT N/A
- YMAB $17.00
- AVG Volume (30 Days)
- PHT 85.5K
- YMAB 185.8K
- Earning Date
- PHT 01-01-0001
- YMAB 08-11-2025
- Dividend Yield
- PHT 8.76%
- YMAB N/A
- EPS Growth
- PHT N/A
- YMAB N/A
- EPS
- PHT 0.98
- YMAB N/A
- Revenue
- PHT N/A
- YMAB $88,658,000.00
- Revenue This Year
- PHT N/A
- YMAB N/A
- Revenue Next Year
- PHT N/A
- YMAB $15.15
- P/E Ratio
- PHT $7.71
- YMAB N/A
- Revenue Growth
- PHT N/A
- YMAB 4.92
- 52 Week Low
- PHT $6.41
- YMAB $3.55
- 52 Week High
- PHT $7.60
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- PHT 53.87
- YMAB 45.90
- Support Level
- PHT $8.09
- YMAB $4.20
- Resistance Level
- PHT $8.16
- YMAB $4.42
- Average True Range (ATR)
- PHT 0.05
- YMAB 0.22
- MACD
- PHT -0.01
- YMAB -0.01
- Stochastic Oscillator
- PHT 28.57
- YMAB 38.10
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.